Oxford vaccine trials to resume

Share

The vaccine, which is being backed by pharmaceutical giant AstraZeneca, is a leading contender to become the first to go into mass production.

According to instructions issued by DCGI following SII's response on September 10, the Pune firm will only be able to resume vaccination in the Indian trials of this vaccine candidate once it submits safety clearances from DSMB in India as well as the United Kingdom board that reviewed the global safety issue.

The Government of Kazakhstan announced that immunization for Kazakhstanis at risk will be carried out on a free and voluntary basis and is possible only after the vaccine has passed all stages of clinical trials.

"They are starting to manufacture those doses already ahead of approval so that should approval come through, and it's still not certain, but it is looking up.then we're ready to roll out", he said.

RDIF said on Friday that more than one billion people would receive its COVID-19 vaccine "Sputnik-V" in 2020-21, the Interfax news agency reported.

The AZD1222, formerly known as ChAdOx1 nCoV-19, is a weakened form of the common cold virus that has been genetically moderated so that it can not grow in humans.

CLINICAL TRIALS for a Covid-19 vaccine being developed at the University of Oxford are set to resume.

Belarus activists describe dramatic alleged abduction and last sighting of Maria Kolesnikova
Speaking to reporters from her apartment, she said she doesn't plan to leave the country despite the official pressure. Amid Western criticism, Lukashenko has relied on support from Moscow, his main sponsor and ally.

According to AFP, "The researchers identified what they said appeared to be a number of duplications in figures presented and concluded that the data within the study was "highly unlikely" to be correct".

The hiccup shows how risky the technology is, and why Sputnik V is not using it, the Russian vaccine funder's CEO said.

"It is planned that a batch of vaccines for delivery to Kazakhstan will be produced by one of the worldwide partners of RDIF", the Russian fund said in a statement. SII responded to the show cause notice saying that Data and Safety Monitoring Board (DSMB) noted no safety concerns from the Indian study with the first dose and seven day post vaccination data. In fact, Oxford University stopped the vaccine trial on 6 September.

The company said it could not disclose further medical information.

Extolling the benefits of the "Sputnik-V" vaccine, he said that as the vaccine was based on ' human adenoviral vectors", it was proven to be "safe and effective'.

Odoemena said Russia's action also poses a potential health risk, adding that already following Russia's "misstep" is China, which has chose to approve Sinovac's COVID-19 vaccine candidate. This vaccine is now under Phase III of clinical trial and they have recruited thousands of healthy individuals in countries like the UK, India, Brazil and the United States.

Share